| Literature DB >> 29575953 |
Aleksandra Kezić1,2, Svetlana Kovačević1, Jelena Marinković1, Stojanka Ristić2, Dragana Radivojević2, Radmila Blagojević-Lazić2, Ljubica Djukanovic1, Visnja D Ležaić1,2.
Abstract
BACKGROUND: Kidney transplantation from living donors (LD) has stagnated in many countries. This study aimed to check whether correction of LD selection practice could increase the number of kidney transplantations.Entities:
Keywords: Kidney transplantation; donor evaluation; donor risk; living donor; selection criteria
Mesh:
Year: 2018 PMID: 29575953 PMCID: PMC6014375 DOI: 10.1080/0886022X.2018.1450758
Source DB: PubMed Journal: Ren Fail ISSN: 0886-022X Impact factor: 2.606
Figure 1.Number of potential living donors (accepted and unaccepted for donation the kidney) evaluated in the period from 2003 to 2012. The number of potential donors evaluated for donation diminished in the 10 years analyzed, especially after 2010. The rate of acceptance of patients decreased over the 10-year period, i.e., 95.8% of the evaluated donors were accepted in 2005 but 30.4% in 2010.
Death numbers and standardized mortality ratio (SMR) of evaluated donors.
| Age | Person-years | Deaths |
|---|---|---|
| 20–39 | 57.83 | 0 |
| 40–44 | 133.00 | 0 |
| 45–49 | 226.50 | 3 |
| 50–54 | 249.17 | 4 |
| 55–64 | 763.67 | 4 |
| 65–74 | 464.17 | 10 |
| +75 | 93.92 | 4 |
| Total | 1988.25 | 25 |
| Death rate | 0.01257 | |
| SMR (95% CI)a | 1.104 (0.730–1.606) | |
According to the population in Serbia matched by age.
Reasons of not accepting evaluated donors for donation.
| Reasons | Number of patients | |
|---|---|---|
| Recipients | Deceased kidney transplantation | 1 |
| Histocompatibility mismatches | 4 | |
| Cancer de novo | 1 | |
| Othera | 5 | |
| Donors | Kidney diseaseb | 5 |
| eGFR <80 ml/min/1.73 m2 | 5 | |
| Kidney stone | 2 | |
| Multiple cysts | 3 | |
| Cardiovascular diseasesc | 3 | |
| Needs prior surgery | 2 | |
| Cancer de novo (breast, lung) | 2 | |
| Older age | 5 | |
| Withdrawn before evaluation complete | 21 |
High risk of bleeding due to antiphospholipid syndrome or hereditary macrothrombocytopaenia.
Albuminuria <30 mg/24 h, or proteinuria <200 mg/24 h, or persistent microhaemathuria.
Uncontrolled hypertension (with >2 anti hypertensive medications), cardiovascular disease (ischemic heart disease, cardiac failure).
Baseline data on studied potential donors at the time of pre-donation evaluation.
| Unaccepted donors | Accepted donors | ||
|---|---|---|---|
| Sex, f/m | 24/35 | 65/117 | .535 |
| Age | 61.41 ± 1.13 | 56.76 ± 0.78 | .0024 |
| Distributionb | |||
| 20–39 | 1 | 9 | .458 |
| 40–44 | 1 | 15 | .128 |
| 45–49 | 6 | 24 | .653 |
| 50–54 | 7 | 22 | 1.000 |
| 55–64 | 22 | 67 | 1.000 |
| 65–74 | 14 | 33 | .349 |
| +75 | 8 | 4 | .002 |
| Co-morbiditiesb | |||
| Cardiovascular diseases | 8 (13.6%) | 20 (11%) | .641 |
| Hypertension | 24 (40.7%) | 60 (30%) | .345 |
| Pulmonary | 3 (5.1%) | 16(8.8%) | .577 |
| GID | 13 (22%) | 22 (12%) | .086 |
| GUT | 9 (15.3%) | 37 (20.3%) | .450 |
| Inflammation | 8 (18.6%) | 11 (6%) | .091 |
| Blood pressure, mmHg | |||
| Systolic | 119.52 ± 6.42 | 115.6 ± 4.13 | .629 |
| Diastolic | 73.3 ± 3.84 | 72.0 ± 2.56 | .795 |
| 99mDTPA mGFR, ml/min/1.73m2 | 78.47 ± 5.60 | 87.17 ± 3.79 | .030 |
| Habitsb | |||
| Smoking | 10 (5.9%) | 2 (13.2%) | .519 |
| Alcohol abuse | 1 (0.01%) | 4 (2.2%) | 1.000 |
| Follow-upc, months | 96 | 108 | |
| IQR | 60 | 48 | |
| Events | |||
| ESRD | 0 | 0 | .803 |
| Death | 7 (11.8%) | 18 (9.8%) | |
| 15 years projected ESRD risk | 0.288 ± 0.048 | 0.194 ± 0.015 | .013 |
| Lifetime projected ESRD risk | 0.669 ± 0.098 | 0.427 ± 0.03 | .002 |
| 15 years projected ESRD risk, % | |||
| <1 | 93.4% | 98.4% | |
| 1–2 | 5% | 1.6% | |
| 2–3 Lifetime projected ESRD risk, % | 1.6% | ||
| <1 | 81.4% | 91.3% | |
| 1–2 | 11.8% | 8.7% | |
| 2–3 | 3.4% | ||
| 3–5 | 3.4% | ||
| Causes of death,b | |||
| Cardiovascular diseases | |||
| Malignancies | 1 | 10 | |
| Cirrhosis | 1 | 2 | |
| Unknown | 5 | 6 | |
ESRD: end-stage renal disease; GID: gastrointestinal diseases; GUT: genito-urinary tract diseases; IQR: interquartile range; mGFR: measured glomerular filtration rate.
amean ± SE, bnumber of patients, cmedian.
Figure 2.Kaplan–Meier curves of cumulative proportion surviving across those groups with number of donors at risk. Survival was not significantly different in the accepted donors full line (median 108 months; IQR 48) [log rank test 1.014, p = .314] when compared with the unaccepted donor group (median 96 months, IQR 60).